| Skin Cancer |
1 |
1 |
| Tumor |
0 |
0.96 |
| Basal Cell Carcinoma |
0 |
0.64 |
| Dermatitis |
0 |
0.4 |
| Genomic Medicine |
0 |
0.29 |
| Histone Deacetylase Inhibitor |
0 |
0.24 |
| Social Determinants of Health |
0 |
0.23 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.19 |
| Wound Management |
0 |
0.19 |
| Nevoid Basal Cell Carcinoma Syndrome (NBCCS) |
0 |
0.12 |
| Stem Cell Research and Therapy |
0 |
0.11 |
| Drug Reaction |
0 |
0.09 |
| Id Reaction |
0 |
0.09 |
| Mohs Surgery |
0 |
0.09 |
| Surgery |
0 |
0.09 |
| Cancer |
0 |
0.06 |
| Cutaneous T-Cell Lymphoma |
0 |
0.05 |
| Allograft |
0 |
0.03 |
| Biopsy |
0 |
0.03 |
| Brachial |
0 |
0.03 |
| California |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Diversity |
0 |
0.03 |
| Epigenetics |
0 |
0.03 |
| Face |
0 |
0.03 |
| Fellowship |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Health Care Quality, Access, and Evaluation |
0 |
0.03 |
| Histology |
0 |
0.03 |
| Lymphoma |
0 |
0.03 |
| Oncogene |
0 |
0.03 |
| Scar |
0 |
0.03 |
| Students |
0 |
0.03 |
| T-Lymphocyte |
0 |
0.03 |
| Topical Therapy |
0 |
0.03 |